Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) motto: Q2/18 ends with Q3 coming attractions or reaction?

July 6, 2018 12:25pm

For continued access to what one industry CEO calls the “Bible” for smart investing in the RegMed, gene and cell therapy sector, click on the button below:

http://www.regmedinvestors.com/create-account

Why spend time searching for sector news and analytics … it’s all right here!

Review daily indicators – pre-open and close, trends – whether they’re your friend or not, advance/decline lines of 45 covered companies, volatility responses followed by the factors involving decliners versus gainers and their daily percentages.

I “never leave an investor uninformed”

Learn who is stumbling and what the mumbling means …

RMi is the only source of actionable intelligence for the stem, cell and gene therapy and regenerative medicine’s universe.

You’ve enjoyed complimentary access to unbiased analysis, in-depth analytics, informational synthesis and their potential for gains and losses.

Try subscription, you’d make a return on its investment!

http://www.regmedinvestors.com/create-account

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.